At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 217 enrolled
Drug / intervention
lenalidomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating lenalidomide for Lymphoma, Non-Hodgkin's. Completed, enrolled 217 participants across 53 sites in 7 countries.
Detailed Summary
Subjects who qualify will receive oral lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue until disease progression, or unacceptable adverse events develop
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin's
CountriesCanada, France, Germany, Italy, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedDec 2006
Primary CompletionApr 2011
Study CompletionMay 2011
TodayJul 2026
First PostedDec 19, 2006
Enrollment StartJun 1, 2006
Primary CompletionApr 1, 2011
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 19.5 years ago
Interventions
lenalidomidedrug
once daily oral capsule